Who are II Consolidation HiDAraC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Consolidation, III HiDAraC cycle.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ii-consolidation-hidarac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

II Consolidation HiDAraC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

II Consolidation HiDAraC (II Consolidation HiDAraC) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog / Antimetabolite chemotherapy. Area: Oncology.

phase 3 Nucleoside analog / Antimetabolite chemotherapy DNA synthesis (cytidine deaminase inhibition pathway) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

II Consolidation HiDAraC (II Consolidation HiDAraC) — dr hab. n. med. Agnieszka Wierzbowska. II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
II Consolidation HiDAraC TARGET	II Consolidation HiDAraC	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA synthesis (cytidine deaminase inhibition pathway)
Consolidation, III HiDAraC cycle	Consolidation, III HiDAraC cycle	dr hab. n. med. Agnieszka Wierzbowska	phase 3	Nucleoside analog / Antimetabolite chemotherapy	DNA/RNA synthesis (cytidine deaminase inhibition pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog / Antimetabolite chemotherapy class)

dr hab. n. med. Agnieszka Wierzbowska · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). II Consolidation HiDAraC — Competitive Intelligence Brief. https://druglandscape.com/ci/ii-consolidation-hidarac. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab